Deutsche Bank: Gold Price Bubble Highly Probable

Source: Financial Times, Chris Flood (1/13/11)

"A collapse of the dollar cannot be dismissed out of hand."

The formation of a gold price bubble is a "high probability event," warns Deutsche Bank Commodity Strategist Michael Lewis. He says that the price of gold would need to rise above $2,000/oz. to represent a bubble but he notes the factors that have driven the market higher in recent years are likely to continue in 2011.

Expecting U.S. real (inflation-adjusted) interest rates to remain negative, an environment that historically has seen gold (and silver) perform well, Lewis also warns that a collapse of the dollar "cannot be dismissed out of hand" given the significant fiscal consolidation required in the U.S.

He also expects central banks, particularly in Asia, to diversify their foreign exchange reserves further by increasing their gold holdings and says inflows into gold ETFs will continue rising, reflecting investors' desire for protection against the twin threats of deflation or rising inflation.

The value of investors' holdings in gold ETFs ended 2010 at $98B—a record, even though last year's inflows into gold ETFs were substantially lower than in 2009.

Last year's rise in gold prices helped to increase the value of gold ETF holdings 40.2% from $69.9B at the end of 2009.

According to Barclays Capital, inflows into gold ETFs were 330 tons in 2010—down almost half from 614 tons in 2009. Total gold ETF holdings were 2,140 tons at year-end 2010, slightly below mid-December's all-time high of 2,155 tons.

Investment buying (ETFs, coins and bars) has become an increasingly important source of total gold demand, rising from just over 10% in 2000 to an estimated 40% last year.

Barclays Capital Precious Metals Analyst Suki Cooper says investment demand for gold is likely to slow toward the end of 2011—but it will still be strong enough to push the price to a fresh record high.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.